» Articles » PMID: 32342443

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study

Overview
Date 2020 Apr 29
PMID 32342443
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA.

Methods: We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design.

Results: Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants.

Conclusions: Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects.

Citing Articles

Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia.

Parikh A, J Tan I, Wolfe S, Cohen B Life (Basel). 2025; 14(12.

PMID: 39768285 PMC: 11677532. DOI: 10.3390/life14121577.


Alopecia Areata: Current Treatments and New Directions.

Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E Am J Clin Dermatol. 2023; 24(6):895-912.

PMID: 37606849 DOI: 10.1007/s40257-023-00808-1.


Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment.

Park H, Kim J, Choi J, Kim D, Jang Y, Lee Y Ann Dermatol. 2023; 35(3):190-204.

PMID: 37290953 PMC: 10258548. DOI: 10.5021/ad.22.168.


Differential impact of environmental factors on systemic and localized autoimmunity.

Touil H, Mounts K, De Jager P Front Immunol. 2023; 14:1147447.

PMID: 37283765 PMC: 10239830. DOI: 10.3389/fimmu.2023.1147447.


The Role of Nutrition in Immune-Mediated, Inflammatory Skin Disease: A Narrative Review.

Diotallevi F, Campanati A, Martina E, Radi G, Paolinelli M, Marani A Nutrients. 2022; 14(3).

PMID: 35276950 PMC: 8840467. DOI: 10.3390/nu14030591.


References
1.
Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L . Vitamin D3: a helpful immuno-modulator. Immunology. 2011; 134(2):123-39. PMC: 3194221. DOI: 10.1111/j.1365-2567.2011.03482.x. View

2.
Strazzulla L, Chun Wang E, Avila L, Lo Sicco K, Brinster N, Christiano A . Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2017; 78(1):1-12. DOI: 10.1016/j.jaad.2017.04.1141. View

3.
Lee S, Lee W . Management of alopecia areata: Updates and algorithmic approach. J Dermatol. 2017; 44(11):1199-1211. DOI: 10.1111/1346-8138.13933. View

4.
Ganzetti G, Campanati A, Scocco V, Brugia M, Tocchini M, Liberati G . The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014; 94(6):715-7. DOI: 10.2340/00015555-1801. View

5.
Hewison M . An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2011; 76(3):315-25. DOI: 10.1111/j.1365-2265.2011.04261.x. View